Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

PSMA-PET response under [<sup>177</sup>Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteria.

European journal of nuclear medicine and molecular imaging·2026
Same author

Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901).

European urology·2026
Same author

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617.

Radiology·2026
Same author

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

The Lancet. Oncology·2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Related Experiment Video

Updated: Jul 24, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.

Rudolf A Werner1, Philipp E Hartrampf2, Wolfgang P Fendler3

  • 1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany; The Russell H Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

European Urology
|July 6, 2023
PubMed
Summary
This summary is machine-generated.

The Prostate-Specific Membrane Antigen Reporting and Data System (PSMA-RADS) version 2.0 refines lesion characterization for prostate cancer detection on PSMA-PET imaging. This updated framework aims to improve clinical decision-making and overcome limitations of the previous version.

Keywords:
Prostate carcinomaProstate-specific membrane antigenReporting and data systemStructured reporting

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.9K

Related Experiment Videos

Last Updated: Jul 24, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.9K

Area of Science:

  • Nuclear medicine
  • Radiopharmaceuticals
  • Oncology

Background:

  • The Prostate-Specific Membrane Antigen Reporting and Data System (PSMA-RADS) version 1.0 standardizes reporting for PSMA-targeted PET imaging in prostate cancer.
  • Evidence supports PSMA-RADS 1.0 categories reflecting actual lesion positivity and demonstrates high interobserver agreement across various radiotracers.
  • The system aids in clinical decisions, including managing oligometastatic disease, but has limitations, particularly in follow-up assessments of treated lesions.

Purpose of the Study:

  • To update the PSMA-RADS framework to version 2.0.
  • To introduce refined categories for optimized lesion-level characterization.
  • To enhance clinical decision-making support in prostate cancer management.

Main Methods:

  • Systematic review and expert consensus on PSMA-RADS 1.0 performance and limitations.
  • Development of new categories and criteria for PSMA-RADS version 2.0.
  • Validation of the updated framework in diverse clinical scenarios.

Main Results:

  • PSMA-RADS 1.0 categories generally correlate with true lesion positivity.
  • High interobserver agreement observed with 68Ga- and 18F-labeled PSMA tracers.
  • Identified limitations in PSMA-RADS 1.0 for follow-up assessments necessitate an updated framework.

Conclusions:

  • PSMA-RADS version 2.0 offers an improved framework for lesion characterization in PSMA-PET imaging.
  • The updated system aims to enhance diagnostic accuracy and clinical utility.
  • Refined categories in PSMA-RADS 2.0 will better assist in prostate cancer management and treatment decisions.